Kadcyla is an antibody drug conjugate (ADC), which combines the HER2-targeting properties of Herceptin (trastuzumab) and the cytotoxic chemotherapy agent DM1. In Kadcyla, trastuzumab and DM1 are joined together using a ‘stable linker’ to deliver DM1 directly to HER2-positive cancer cells.
Kadcyla is approved as a single agent in the US, EU and many other countries for the treatment of people with HER2-positive advanced breast cancer who previously received Herceptin and taxane chemotherapy, separately or in combination. These people must have either already been treated for their advanced disease or have had their disease return during, or within, six months after they completed a course of treatment following surgery.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions. See our information for details on how to report.